XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression

Clinical Lung Cancer

Volumn 10, Issue 1, 2009, Pages 47-52

  Bartolucci, Roberta ^a   Wei, Jia ^b,c   Sanchez, Jose Javier ^d   Perez Roca, Laia ^b   Chaib, Imane ^b   Puma, Francesco ^a   Farabi, Raffaele ^a   Mendez, Pedro ^b   Roila, Fausto ^a   Okamoto, Tatsuro ^b   Taron, Miquel ^b,e   Rosell, Rafael ^b,e,f  

^a S MARIA HOSPITAL   (Italy)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c NANJING UNIVERSITY   (China)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e INSTITUT UNIVERSITARI DEXEUS   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

DNA repair; Homologous recombination repair; Nucleotide excision repair; Xeroderma pigmentosum group G

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP G PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

EID: 62549161737     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.007     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized trials including 4,584 patients. J Clin Oncol 2008; 26:3552-9.
3. Choy H, Pass H, Rosell R, et al. Lung cancer. In: Chang AE, Ganz PA, Hayes DF, et al, eds. Oncology: An Evidence-Based Approach. New York, NY: Springer Science+Business Media, Inc; 2006:545-621.
4. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
5. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer [published erratum in: N Engl J Med 2007; 356:201-2]. N Engl J Med 2006; 355:570-80.
6. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008; 14:4794-9.
7. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008; 14:5565-70.
8. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007; 2:e1129.
9. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54.
10. Sugasawa K. Xeroderma pigmentosum genes: functions inside and outside DNA repair. Carcinogenesis 2008; 29:455-65.
11. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-9.
12. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22:3548-53.
13. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25.
14. Su TT. Cellular responses to DNA damage: one signal, multiple choices. Annu Rev Genet 2006; 40:187-208.
15. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180-92.
16. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5.
17. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008; 68:6884-8.
18. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006; 98:472-82.
19. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008; 27:565-73.
20. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007; 28:739-45.
21. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6.
22. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-8.
23. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13:7413-20.
24. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-22.
25. Deeb KK, Michalowska AM, Yoon CY, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis [published erratum in: Cancer Res 2007; 67:10067]. Cancer Res 2007; 67:8065-80.
26. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
27. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8.
28. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000; 89:453-7.
29. Eelen G, Vanden Bempt I, Verlinden L, et al. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene 2008; 27:4233-41.
30. Sobhian B, Shao G, Lilli DR, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316:1198-202.
31. Chen X, Arciero CA, Wang C, et al. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res 2006; 66:5039-46.
32. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000; 407:102-6.
33. Mo X, Kowenz-Leutz E, Xu H, et al. Ras induces mediator complex exchange on C/EBP beta. Mol Cell 2004; 13:241-50.
34. Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008; 455:547-51.